uc-781

Small moleculeexperimental

Clinical trial activity

5 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 2005 (NCT00132444)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • 2-chloro-5-(((2-methyl-3-furanyl)carbonothioyl)amino)phenyl 3-methyl-2-butenyl ether
  • uc781
  • uc 781
  • uc-781
  • uc-781
  • uc-781
  • uc-781

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00446979Phase 1Jun 1, 2007Centers for Disease Control and Prevention (CDC), CONRAD, Government of Thailand, Thailand MOPH - U.S. CDC Collaboration
NCT00408538Phase 1Dec 1, 2006CONRAD, National Institute of Allergy and Infectious Diseases (NIAID), University of California, Los Angeles
NCT00385554Phase 1Oct 5, 2006CDC Botswana, Centers for Disease Control and Prevention (CDC), CONRAD
NCT00441909Phase 1Apr 1, 2006CONRAD, National Institute of Allergy and Infectious Diseases (NIAID), University of Pittsburgh
NCT00132444Phase 1Oct 1, 2005Centers for Disease Control and Prevention (CDC), CONRAD, Emory University
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CONRADFor profit5112005
Centers for Disease Control and Prevention (CDC)Government3212005
National Institute of Allergy and Infectious Diseases (NIAID)Government2112006
CDC BotswanaGovernment1012006
Emory UniversityAcademic/Hospital1012005
Government of ThailandGovernment1012007
Thailand MOPH - U.S. CDC CollaborationGovernment1012007
University of California, Los AngelesAcademic/Hospital1112006
University of PittsburghAcademic/Hospital1012006
9 organizations
Page 1 / 1